,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-08-02 07:12:00,"Chicago, IL - August 02, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog.",0.018063046038150787,0.008616172708570957,0.9733207821846008,neutral,0.00944687332957983
1,2017-08-02 07:12:00,Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.,0.021041298285126686,0.011407552286982536,0.9675511121749878,neutral,0.00963374599814415
2,2017-08-02 07:12:00,"Stocks recently featured in the blog includeProcter & Gamble (NYSE: PG - Free Report ), Altria (NYSE: MO - Free Report ), Bristol-Myers (NYSE: BMY - Free Report ), ConocoPhillips (NYSE: COP - Free Report ) and Electronic Arts (NASDAQ: EA - Free Report ).",0.021281132474541664,0.013761619105935097,0.9649572372436523,neutral,0.007519513368606567
3,2017-08-02 07:12:00,"Today, Zacks is promoting its ''Buy'' stock recommendations.",0.3684377670288086,0.010614300146698952,0.6209479570388794,neutral,0.3578234612941742
4,2017-08-02 07:12:00,Get #1Stock of the Day pick for free.,0.0864095613360405,0.03249066323041916,0.8810997605323792,neutral,0.05391889810562134
5,2017-08-02 07:12:00,"Here are highlights from Tuesday's Analyst Blog:

The Zacks Research Daily presents the best research output of our analyst team.",0.23975257575511932,0.009843643754720688,0.7504038214683533,neutral,0.22990892827510834
6,2017-08-02 07:12:00,"Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (NYSE: PG - Free Report ), Altria (NYSE: MO - Free Report ) and Bristol-Myers (NYSE: BMY - Free Report ).",0.04373412951827049,0.007595409173518419,0.9486704468727112,neutral,0.03613872081041336
7,2017-08-02 07:12:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
8,2017-08-02 07:12:00,"You can see all of today's research reports here >>>

Buy-rated Procter & Gamble shares have outperformed the Zacks Consumer Staples sector in the past year (+4.8% vs. +2.1%).",0.7959122061729431,0.1748461276292801,0.029241641983389854,positive,0.6210660934448242
9,2017-08-02 07:12:00,"However, P&G shares have underperformed the S&P 500 index in the year-to-date period (up +8.1% vs. +10.5%).",0.2713909447193146,0.708956241607666,0.0196528397500515,negative,-0.43756529688835144
10,2017-08-02 07:12:00,P&G's earnings and revenues surpassed expectations in fourth-quarter fiscal 2017.,0.9467010498046875,0.01840164139866829,0.03489729389548302,positive,0.9282994270324707
11,2017-08-02 07:12:00,Adjusted earnings increased 8% year over year but net sales remained unchanged with the year-ago level.,0.9202502965927124,0.04211103916168213,0.037638649344444275,positive,0.8781392574310303
12,2017-08-02 07:12:00,The company has been struggling to boost market growth for the last few quarters.,0.04908083751797676,0.9198678731918335,0.03105132281780243,negative,-0.8707870244979858
13,2017-08-02 07:12:00,But the Zacks analyst likes the fact that P&G is speeding up innovations and investments to counter softening industry growth.,0.8218693733215332,0.017717216163873672,0.16041336953639984,positive,0.8041521310806274
14,2017-08-02 07:12:00,"Its productivity improvements and aggressive cost-saving efforts, projected to save $10 billion over the next five years, are also consistently helping to boost profit levels.",0.9534759521484375,0.020016031339764595,0.02650798298418522,positive,0.9334599375724792
15,2017-08-02 07:12:00,(You can read the full research report on Procter & Gamble here >>> ) .,0.013788774609565735,0.010992237366735935,0.9752189517021179,neutral,0.0027965372428297997
16,2017-08-02 07:12:00,"Sharesof Altria have lagged the Zacks Tobacco industry in the year-to-date period, with the stock down -3.1% vs. the peer group's +12.2% gain.",0.019161920994520187,0.9691972732543945,0.011640825308859348,negative,-0.9500353336334229
17,2017-08-02 07:12:00,Both Altria's earnings and revenues grew year-over-year in the second quarter 2017 driven by strong cigarette pricing and increase in smokeless products.,0.954906702041626,0.017146652564406395,0.027946678921580315,positive,0.937760055065155
18,2017-08-02 07:12:00,"Altria, the U.S.-based entity whose international sibling is Phillips Morris International (PM), is operating in a mature and heavily regulated market that has been undergoing consistent volume declines over the last many years.",0.028558172285556793,0.9291070103645325,0.042334798723459244,negative,-0.9005488157272339
19,2017-08-02 07:12:00,But the strength of Marlboro brand and a solid portfolio or low-risk smokeless tobacco products positions it to profitably navigate this market.,0.925884485244751,0.014295543543994427,0.05981991067528725,positive,0.9115889668464661
20,2017-08-02 07:12:00,"Further, the takeover of SABMiller by Anheuser-Busch InBev has helped Altria maximize the value of its SABMiller investment.",0.9464806914329529,0.014113855548202991,0.0394054614007473,positive,0.9323668479919434
21,2017-08-02 07:12:00,"An attractive dividend, currently yielding 3.8%, is a notable part of this story as well.",0.4126851260662079,0.010327736847102642,0.5769871473312378,neutral,0.40235739946365356
22,2017-08-02 07:12:00,(You can read the full research report on Altria here >>> ) .,0.014041485264897346,0.01390156801789999,0.9720569252967834,neutral,0.00013991724699735641
23,2017-08-02 07:12:00,"Bristol-Myers 's shares have underperformed the broader market as well as the large cap pharma group this year, losing -2.5% in the year-to-date period.",0.020816268399357796,0.9690244197845459,0.010159337893128395,negative,-0.9482081532478333
24,2017-08-02 07:12:00,"Bristol-Myers delivered yet another strong quarter with the top and the bottom line beating expectations driven by sales of drugs like Opdivo, Eliquis and Yervoy.",0.9474436044692993,0.027462996542453766,0.025093385949730873,positive,0.9199805855751038
25,2017-08-02 07:12:00,"Meanwhile, Bristol-Myers is looking to expand Opdivo's label further which should boost performance.",0.9546923637390137,0.017517438158392906,0.02779012732207775,positive,0.937174916267395
26,2017-08-02 07:12:00,"However, Opdivo is currently facing competitive challenges in the U.S. With the FDA approving Merck's Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to see further loss of market share.",0.017124118283391,0.9602879881858826,0.022587858140468597,negative,-0.9431638717651367
27,2017-08-02 07:12:00,Shares were down after Q2 results as concerns from AstraZeneca's failed study on lung cancer drug Imfinzi loomed large on the company's CheckMate 227 study on Opdivo.,0.017411643639206886,0.9667989611625671,0.01578948274254799,negative,-0.9493873119354248
28,2017-08-02 07:12:00,(You can read the full research report on Bristol-Myers here >>> ) .,0.013764891773462296,0.012010612525045872,0.9742245078086853,neutral,0.0017542792484164238
29,2017-08-02 07:12:00,Other noteworthy reports we are featuring today include ConocoPhillips (NYSE: COP - Free Report ) and Electronic Arts (NASDAQ: EA - Free Report ).,0.04307664558291435,0.006068130023777485,0.9508551955223083,neutral,0.03700851649045944
30,2017-08-02 07:12:00,"Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar.",0.04345273599028587,0.020456276834011078,0.9360910058021545,neutral,0.022996459156274796
31,2017-08-02 07:12:00,Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential?,0.33031973242759705,0.014298503287136555,0.6553817391395569,neutral,0.31602123379707336
32,2017-08-02 07:12:00,This Special Report gives you the current scoop on 5 that may go public at any time.,0.019046178087592125,0.008929912000894547,0.9720239043235779,neutral,0.010116266086697578
33,2017-08-02 07:12:00,One has driven from 0 to a $68 billion valuation in 8 years.,0.6626474857330322,0.01823992282152176,0.319112628698349,positive,0.6444075703620911
34,2017-08-02 07:12:00,Four others are a little less obvious but already show jaw-dropping growth.,0.2814808785915375,0.08773558586835861,0.6307835578918457,neutral,0.19374528527259827
35,2017-08-02 07:12:00,"Download this IPO Watch List today for free >>

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.",0.06342748552560806,0.005020895507186651,0.9315515756607056,neutral,0.05840659141540527
36,2017-08-02 07:12:00,"Continuous coverage is provided for a universe of 1,150 publicly traded stocks.",0.036364275962114334,0.004866600502282381,0.9587691426277161,neutral,0.03149767592549324
37,2017-08-02 07:12:00,Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance.,0.054108913987874985,0.005191051866859198,0.9407000541687012,neutral,0.04891786351799965
38,2017-08-02 07:12:00,Recommendations and target prices are six-month time horizons.,0.013092893175780773,0.007127966266125441,0.9797791242599487,neutral,0.0059649269096553326
39,2017-08-02 07:12:00,"Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar.",0.044983625411987305,0.5624399185180664,0.3925764560699463,negative,-0.5174562931060791
40,2017-08-02 07:12:00,They're virtually unknown to the general public.,0.035764459520578384,0.0785161554813385,0.885719358921051,neutral,-0.04275169596076012
41,2017-08-02 07:12:00,"Yet today's 220 Zacks Rank #1 ""Strong Buys"" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015.",0.6580293774604797,0.017276067286729813,0.32469451427459717,positive,0.6407533288002014
42,2017-08-02 07:12:00,Its average gain has been a stellar +26% per year.,0.8422174453735352,0.0191669799387455,0.13861553370952606,positive,0.8230504393577576
43,2017-08-02 07:12:00,See these high-potential stocks free >>.,0.12527841329574585,0.05778927728533745,0.8169323205947876,neutral,0.0674891322851181
44,2017-08-02 07:12:00,"Get the full Report on PG - FREE

Get the full Report on MO - FREE

Get the full Report on BMY - FREE

Get the full Report on COP - FREE

Get the full Report on EA - FREE

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",0.013178917579352856,0.009637130424380302,0.9771839380264282,neutral,0.0035417871549725533
45,2017-08-02 07:12:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
46,2017-08-02 07:12:00,Inherent in any investment is the potential for loss.,0.023265572264790535,0.09617827832698822,0.8805561661720276,neutral,-0.07291270792484283
47,2017-08-02 07:12:00,"This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.011962415650486946,0.010706594213843346,0.9773310422897339,neutral,0.0012558214366436005
48,2017-08-02 07:12:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
49,2017-08-02 07:12:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
50,2017-08-02 07:12:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
51,2017-08-02 07:12:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
52,2017-08-02 07:12:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
53,2017-08-02 07:12:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
54,2017-08-02 07:12:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
55,2017-08-02 07:12:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
56,2017-08-02 07:12:00,Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01078665629029274,0.015373211354017258,0.9738401174545288,neutral,-0.004586555063724518
57,2017-08-02 07:12:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
58,2017-08-02 07:12:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
59,2017-08-02 07:12:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
60,2017-08-02 07:12:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
